Wnt signaling in triple-negative breast cancer

Sö-G Pohl; N Brook; M Agostino; F Arfuso; A P Kumar; A Dharmarajan

doi:10.1038/oncsis.2017.14

Wnt signaling in triple-negative breast cancer

Oncogenesis. 2017 Apr 3;6(4):e310. doi: 10.1038/oncsis.2017.14.

Authors

Sö-G Pohl^{1

2

3}, N Brook^{1

2

3}, M Agostino^{1

2

3

4}, F Arfuso^{1

2

3}, A P Kumar^{2

3

5

6

7}, A Dharmarajan^{1

2

3}

Affiliations

¹ Stem Cell and Cancer Biology Laboratory, Perth, WA, Australia.
² School of Biomedical Sciences, Curtin University, Perth, WA, Australia.
³ Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
⁴ Curtin Institute for Computation, Curtin University, Perth, WA, Australia.
⁵ Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
⁶ Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Translational Medicine, Singapore, Singapore.
⁷ Department of Biological Sciences, University of North Texas, Denton, TX, USA.

Abstract

Wnt signaling regulates a variety of cellular processes, including cell fate, differentiation, proliferation and stem cell pluripotency. Aberrant Wnt signaling is a hallmark of many cancers. An aggressive subtype of breast cancer, known as triple-negative breast cancer (TNBC), demonstrates dysregulation in canonical and non-canonical Wnt signaling. In this review, we summarize regulators of canonical and non-canonical Wnt signaling, as well as Wnt signaling dysfunction that mediates the progression of TNBC. We review the complex molecular nature of TNBC and the emerging therapies that are currently under investigation for the treatment of this disease.

Publication types

Review